DEA Denies Weed Biz License: No Secure Cabinet, No Deal!
Published Date: 9/29/2026
Notice
Summary
JT Medical, LLC tried to get a DEA registration to handle marijuana but didn’t meet the rules because they couldn’t prove they had a real supply deal or a secure storage cabinet. Since they didn’t respond to the government’s concerns on time, their application was denied. This means JT Medical can’t legally handle marijuana products, and anyone working with them should look for other options.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA denies JT Medical's marijuana registration
The Drug Enforcement Administration denied JT Medical, LLC's application for a DEA manufacturer registration (Control No. W17047690E) and any other pending related applications in Pennsylvania. The Order is effective October 29, 2026, so JT Medical is not registered to manufacture schedule I substances listed (marihuana, marihuana extract, and tetrahydrocannabinol).
Must show supply deal and secure storage
The Agency emphasized that applicants must demonstrate a bona fide supply agreement to meet anticipated demand and must have effective physical security for schedule I/II materials. For example, finished products in Schedule I or II must be stored in a safe or steel cabinet which, if under 750 pounds, must be bolted or cemented to the floor or wall.
Can reapply under new state-license pathway
The denial does not prevent JT Medical from submitting an application under the new framework created for entities holding state medical marijuana licenses. The Federal Register rule referenced (91 FR 22714, 22721 (2026)) adds an expedited review process for state-licensed medical marijuana entities and places certain marijuana products in Schedule III subject to a state medical marijuana license.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-19841, Inflation Adjustment for EOIR OBBBA Fees for Certain DHS Forms; Fiscal Year 2027
Starting October 1, 2026, the Department of Justice is raising fees for certain immigration forms filed with the Executive Office for Immigration Review to keep up with inflation. This affects folks using forms like I-485, I-589, I-601, and I-821. The fee changes help cover costs but don’t affect other DHS fees, so get ready for a small price bump next fiscal year!
Next: 2026-19844, Angela Turner-Brown, N.P.; Decision and Order
Angela Turner-Brown, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal authority to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on July 31, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her professional practice immediately.